Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment

This open‐label, parallel‐group, multicenter study aimed to assess the effects of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of luseogliflozin. A single 5‐mg dose of luseogliflozin was administered to Japanese patients with type 2 diabetes mellitus in the following groups...

Descripción completa

Detalles Bibliográficos
Autores principales: Samukawa, Yoshishige, Haneda, Masakazu, Seino, Yutaka, Sasaki, Takashi, Fukatsu, Atsushi, Kubo, Yusuke, Sato, Yuri, Sakai, Soichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220780/
https://www.ncbi.nlm.nih.gov/pubmed/29693800
http://dx.doi.org/10.1002/cpdd.456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220780/
https://www.ncbi.nlm.nih.gov/pubmed/29693800
http://dx.doi.org/10.1002/cpdd.456

Ejemplares similares